VERMILLION, INC. Form 8-K March 21, 2016 SECURITIES AND EXCHANGE COMMISSION	
Washington, D.C. 20549	
Form 8-K	
CURRENT REPORT	
Pursuant to Section 13 or 15(d) of the	
Securities Exchange Act of 1934	
Date of Report (Date of earliest event reported): March 18, 2016	
Vermillion, Inc.	
Exact name of registrant as specified in its charter)	
Commission File Number: 001-34810	
Delaware 33-059-5156 (State or other jurisdiction (IRS Employer)	
of incorporation) Identification No 12117 Bee Caves Road Building Three, Suite 100, Austin, TX 78738	.)
(Address of principal executive offices, including zip code)	
512.519.0400	

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

(b)

On March 15, 2016, Peter S. Roddy, a director of Vermillion, Inc. (the "Company"), advised the Company that he intends to retire from the board of directors of the Company (the "Board") at the end of his current term and will therefore not stand for re-election to the Board at the Company's 2016 annual meeting of shareholders. Mr. Roddy advised the Company that his decision to retire was not the result of any disagreement with the Company.

Item 8.01 Other Events.

On March 18, 2016, Vermillion, Inc. (the "Company") issued a press release announcing that the U.S. Food and Drug Administration has cleared a second generation OVA1 Test, trademarked Overa. A copy of the Company's press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

4

Vermillion, Inc.

Date: March 21, 2016 By: /s/ Eric J. Schoen

Eric J. Schoen

Vice President, Finance and Chief Accounting Officer

EXHIBIT INDEX

issue

Exhibit No. Description

99.1 Press Release issued by Vermillion, Inc. on March 21, 2016.